phase readout
saveNCT06287450: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
NOT_YET_RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd. Phase: PHASE1. Conditions: Respiratory Syncytial Virus Infections
view source ↗
comments(0)
5-min edit window · permanent after that